Metastatic Adenoid Cystic Carcinoma Clinical Trial
Official title:
Peking Union Medical College Hospital
This study was used to study the diagnostic value of 68Ga-FAPI, a novel fibroblast activating inhibitor, in metastatic adenoid cystic carcinoma（ACC）
68Ga-FAPI is a positron labeled inhibitor of fibroblast activating protein, which has been widely used in malignant tumor imaging in recent years. Adenoid cystic carcinoma (ACC) is a rare epithelial malignant tumor, which usually originates from salivary glands. Its typical characteristics are long clinical course and high rate of distant metastasis. The purpose of this study was to investigate the clinical value of 68Ga Fapi pet/ct in metastatic adenoid cystic carcinoma. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04973683 -
AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer
|
Phase 1 | |
| Recruiting |
NCT05774899 -
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
|
Phase 1/Phase 2 | |
| Completed |
NCT03990571 -
Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
|
Phase 2 | |
| Recruiting |
NCT04883671 -
Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial
|
N/A | |
| Recruiting |
NCT06118086 -
Study of REM-422 in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
|
Phase 1 |